Arcadis Nv · EURONEXT:ARCAD
Arcadis Nv — Merger or Acquisition (October 2022)
17 slides from Arcadis Nv's merger presentation, Oct 5, 2022
Slide 1: Arcadis to acquire DPS Group
Arcadis to acquire DPS Group Continue to accelerate Arcadis’ 2021-2023 ‘Maximizing Impact’ strategy 5 October 2022 Improving Quality of Life
Slide 2: Disclaimer
Disclaimer Statements included in this presentation that are not historical facts The forward-looking statements are based upon our current (including any statements concerning investment objectives, other expectations, plans, estimates, assumptions and beliefs that involve plans and objectives of m
Slide 3: Today's Agenda and Presenters
Today’s Agenda and Presenters 01 Introduction to DPS Group Peter Oosterveer CEO 02 Strategic Rationale 03 Transaction details & Integration Virginie Duperat-Vergne CFO 04 Q&A © Arcadis 2022 3
Slide 4: Accelerates Arcadis' 2021-2023 'Maximizing Impact' Strategy
Accelerates Arcadis’ 2021-2023 ‘Maximizing Impact’ Strategy Key transaction Arcadis and DPS Group highlights Creating a leading global position in consultancy, engineering and construction management for the Life Sciences and Semiconductor manufacturing sectors €295M Growth opportunity Highly comple
Slide 5: A critical service provider to clients in Life Sciences and Semiconductor industry
A critical service provider to clients in Life Sciences and Semiconductor industry • A critical service provider to the Life Sciences and €289M 21% Semiconductor manufacturing 2021 FY CAGR 2019-2021 market Organic Net Net Revenues • Key Sectors: Pharmaceutical, Revenues Biotechnology, Novel €300K Th
Slide 6: A critical service provider to clients in Life Sciences and Semiconductor industry
A critical service provider to clients in Life Sciences and Semiconductor industry Leading provider of comprehensive project services to global leading clients in: Pharmaceutical, Biotechnology, Novel Therapy, Medical Technologies & Semiconductor manufacturing Engineering, Procurement, Construction
Slide 7: Recognized by key clients for deep asset knowledge
Recognized by key clients for deep asset knowledge Design & Engineering for Design & Manufacturing Engineering for Crispr Therapeutics facility Janssen facility Location: Framingham, Massachusetts, US Location: Janssen Biologics site, Ireland © Arcadis 2022 7
Slide 8: Strong track record of profitable growth is solid base for future performance
Strong track record of profitable growth is solid base for future performance Net Revenue splits Net Revenues, growth, EBITDA margin (post Secured Backlog as of 30 June 2022 Based on FY2021 IFRS 16) € millions, and year 4% € millions, % 56% 7.7% 8.3% 9.5% €439M 1.5 year Total Secured Secured Backlog
Slide 9: Increases exposure to highly attractive and resilient Life Sciences and Semiconductor Markets
Increases exposure to highly attractive and resilient Life Sciences and Semiconductor Markets Biopharma market Life Sciences market projected to grow Double Digit Growth Top 15 Pharmaceuticals ~7-8% CAGR over Rates across Sub alone >$100 billion medium term, with Sectors such as Tools per year on R&
Slide 10: Acquisition of DPS caters to increased client need for more integrated offerings
Acquisition of DPS caters to increased client need for more integrated offerings from a trusted advisor What are Life Sciences clients Combination well positioned to meet client needs in Life Sciences sector, but also in looking for Industrial Manufacturing and Technology “Speed to market” DPS clien
Slide 11: Complementary services: turning Arcadis into a one-stop shop, full-service provider
Complementary services: turning Arcadis into a one-stop shop, full-service provider Example of collaboration on the Cell Therapy Facility for Bristol Myers Squibb Arcadis and DPS supporting Bristol Myers Squibb in different stages of the project Life Sciences Client of Arcadis and DPS Civil Structur
Slide 12: Strong revenue and cost synergies to drive solid operational performance
Strong revenue and cost synergies to drive solid operational performance Revenue synergies Cost synergies Combination driving significant revenue growth opportunities Expected full run rate of cost synergies of €8M, or 2.8% of 2021 net revenues Complementarity drives increased cross selling Operatio
Slide 13: Combination of Arcadis, IBI & DPS results in balanced portfolio tailored for high growth end markets
Combination of Arcadis, IBI & DPS results in balanced portfolio tailored for high growth end markets Balanced services portfolio Places focus on high growth Strengthened positions in with cross selling across and resilient end markets key geographies GBA’s with strong client base Net Revenues 2021 F
Slide 14: Fully debt financed and Investment Grade rating expected
Fully debt financed and Investment Grade rating expected Key Transaction Details Financing Credit Rating Closing Leverage Ratio Expected to be around Investment Grade rating upper end of targeted Fully debt financed: Closing expected before financial leverage ratio of by S&P expected Bridge Loan, RC
Slide 15: IBI & DPS integration: structured approach allowing continued focus on clients and operations
IBI & DPS integration: structured approach allowing continued focus on clients and operations Integration Update Key integration milestones IBI transaction successfully ✓ closed 27th of Sept., Day 1 Integrating IBI celebrated Combining Financial Setup of 4th GBA: Infrastructure CallisonRTKL and repo
Slide 16: Delivering on our 2021-2023 'Maximizing Impact' Strategy
Delivering on our 2021-2023 ‘Maximizing Impact’ Strategy Digital leadership Sustainable solutions Focus & Scale IBI Group as accelerator Investing in Energy Transition Operational efficiencies and portfolio • 4th GBA: “Intelligence” • Leading in remediation and water in the adjustments • Digital sol
Slide 17: Q&A
Q&A